The US Food and Drug Administration is cobbling together a pilot program that would give the agency remote access to manufacturer records. It’s another approach the FDA wants to try as it feels out the best way to virtually evaluate regulatory compliance during the COVID-19 pandemic.
The FDA’s Office of Regulatory Affairs – or ORA, which handles all of the agency’s field activities – “is deploying the use of a voluntary mechanism for remote regulatory assessments...